NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $53.5K invested in NeuroSense Therapeutics Warrant in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
1.49% less ownership
Funds ownership: 4.12% → 2.63% (-1.5%)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
51% less capital invested
Capital invested by funds: $109K → $53.5K (-$55.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$74 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$563 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$293 |
NRSNW Hedge Fund Activity: Q4 2022 in Review
4 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2022, worth a combined $53.5K — down 51% from $109K a quarter earlier.
Fund positioning in NRSNW was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Clear Street, adding an estimated $74. The largest seller was Warberg Asset Management, cutting an estimated $563.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2022, down from 5 in Q3 2022.
- Funds reported $53.5K of NeuroSense Therapeutics Warrant stock for Q4 2022, down 51% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2022 and 0 closed out.
- The largest NeuroSense Therapeutics Warrant buyer in Q4 2022 was Clear Street, an estimated $74 added.
- The largest NeuroSense Therapeutics Warrant seller in Q4 2022 was Warberg Asset Management, an estimated $563 sold.
Based on aggregated 13F filings for Q4 2022.